Sanofi, GSK receive nod for Phase 3 trial of COVID-19 vaccine candidate in India

The design of the Phase 3 study, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants, the statement said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3jUSC9L
via IFTTT